Roche plans regulatory filings for promising lung cancer candidate

25 September 2018

Last year’s $1.7 billion takeover of US oncology firm Ignyta is beginning to look like it will pay off for Roche (ROG: SIX), after the Swiss giant announced plans to file for regulatory approval for key pipeline acquisition entrectinib.

In buying Ignyta, Roche took over a pivotal Phase II development program for the orally bioavailable, CNS-active tyrosine kinase inhibitor.

Now the firm has released a positive integrated analysis of data from those clinical trials, showing that entrectinib shrank tumors in 77.4% of people with certain non-small cell lung cancers (NSCLC). NSCLC is the most common type of lung cancer, accounting for 85% of all diagnoses.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK